Homepage > Company > Media > Pharma News > 2018 > Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Former Gilead Sciences R&D chief Norbert Bischofberger named CEO of Kronos Bio

Kronos Bio on Wednesday announced the appointment of former Gilead Sciences head of R&D Norbert Bischofberger as its CEO.

The news comes after Bischofberger disclosed in March his intention to leave the drugmaker at the end of last month, having joined the company in 1990.

Bischofberger remarked "the science behind Kronos is compelling," with the company currently advancing two preclinical programmes targeting MYC and the androgen receptor for the treatment of cancer.

May 23rd, 2018

https://www.firstwordpharma.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)